[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 63, "title": "CEO & Vice Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 994800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Shin J.D., M.B.A.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 406256, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan E. Anderman J.D.", "title": "Senior VP, General Counsel & Corporate Secretary", "fiscalYear": 2024, "totalPay": 541620, "exercisedValue": 0, "unexercisedValue": 6250}, {"maxAge": 1, "name": "Ms. Vered  Bisker-Leib MBA, Ph.D.", "age": 53, "title": "Advisor", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 1531657, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Neil L. Lerner CPA", "age": 57, "title": "Senior VP & Chief Accounting Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Minori  Rosales M.D., Ph.D.", "age": 61, "title": "Senior VP & Head of Clinical Development", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "Senior VP & Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.8, "open": 2.79, "dayLow": 2.79, "dayHigh": 3.05, "regularMarketPreviousClose": 2.8, "regularMarketOpen": 2.79, "regularMarketDayLow": 2.79, "regularMarketDayHigh": 3.05, "payoutRatio": 0.0, "beta": 1.296, "forwardPE": -5.921569, "volume": 1426158, "regularMarketVolume": 1426158, "averageVolume": 1024787, "averageVolume10days": 2088740, "averageDailyVolume10Day": 2088740, "bid": 2.98, "ask": 3.07, "bidSize": 3, "askSize": 3, "marketCap": 518147424, "fiftyTwoWeekLow": 1.19, "fiftyTwoWeekHigh": 4.08, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 2.831, "twoHundredDayAverage": 2.309075, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 326568128, "profitMargins": 0.0, "floatShares": 112160934, "sharesOutstanding": 138282000, "sharesShort": 8108960, "sharesShortPriorMonth": 7392714, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0586, "heldPercentInsiders": 0.11415, "heldPercentInstitutions": 0.58583, "shortRatio": 11.04, "shortPercentOfFloat": 0.111099996, "impliedSharesOutstanding": 171572000, "bookValue": 0.674, "priceToBook": 4.480712, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -62026000, "trailingEps": -0.45, "forwardEps": -0.51, "enterpriseToEbitda": -4.851, "52WeekChange": 1.2878788, "SandP52WeekChange": 0.1513431, "quoteType": "EQUITY", "currentPrice": 3.02, "targetHighPrice": 32.0, "targetLowPrice": 7.0, "targetMeanPrice": 13.2, "targetMedianPrice": 10.5, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 100949000, "totalCashPerShare": 0.73, "ebitda": -67320000, "totalDebt": 9904000, "quickRatio": 7.285, "currentRatio": 7.663, "totalRevenue": 0, "debtToEquity": 10.626, "revenuePerShare": 0.0, "returnOnAssets": -0.31142, "returnOnEquity": -0.51837003, "grossProfits": 0, "freeCashflow": -23926876, "operatingCashflow": -45253000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "CMPX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 7.85714, "regularMarketPrice": 3.02, "marketState": "CLOSED", "postMarketTime": 1755899928, "regularMarketTime": 1755892801, "exchange": "NCM", "messageBoardId": "finmb_266166780", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1617629400000, "postMarketChangePercent": 0.6225172, "postMarketPrice": 3.0388, "postMarketChange": 0.01880002, "regularMarketChange": 0.22, "regularMarketDayRange": "2.79 - 3.05", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1024787, "fiftyTwoWeekLowChange": 1.8299999, "fiftyTwoWeekLowChangePercent": 1.537815, "fiftyTwoWeekRange": "1.19 - 4.08", "fiftyTwoWeekHighChange": -1.06, "fiftyTwoWeekHighChangePercent": -0.25980392, "fiftyTwoWeekChangePercent": 128.78787, "earningsTimestamp": 1754884800, "earningsTimestampStart": 1762864200, "earningsTimestampEnd": 1762864200, "earningsCallTimestampStart": 1754913600, "earningsCallTimestampEnd": 1754913600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.45, "epsForward": -0.51, "epsCurrentYear": -0.54857, "priceEpsCurrentYear": -5.505223, "fiftyDayAverageChange": 0.18899989, "fiftyDayAverageChangePercent": 0.06676082, "twoHundredDayAverageChange": 0.71092486, "twoHundredDayAverageChangePercent": 0.30788296, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-11-02", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "corporateActions": [], "displayName": "Compass Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-08-23"}]